128 related articles for article (PubMed ID: 9210703)
1. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience.
Akbulut H; Soykan I; Yakaryilmaz F; Icii F; Aksoy F; Haznedaroglu S; Yildirim S
Cancer; 1997 Jul; 80(1):8-14. PubMed ID: 9210703
[TBL] [Abstract][Full Text] [Related]
2. Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease.
Shih LY; Liaw SJ; Dunn P; Kuo TT
J Clin Oncol; 1994 Jul; 12(7):1375-82. PubMed ID: 8021727
[TBL] [Abstract][Full Text] [Related]
3. Should we suppress the antigenic stimulus in IPSID for lifelong?
Celik AF; Pamuk GE; Pamuk ON; Uzunismail H; Oktay E; Doğusoy G
Am J Gastroenterol; 2000 Nov; 95(11):3318-20. PubMed ID: 11095373
[No Abstract] [Full Text] [Related]
4. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of Mediterranean abdominal lymphoma. Retrospective comparison of chemotherapy protocols in Iranian patients.
Salimi M; Spinelli JJ
Am J Clin Oncol; 1996 Feb; 19(1):18-22. PubMed ID: 8554029
[TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin's lymphomas in Turkey: eighteen years' experience at the Hacettepe University.
Barista I; Tekuzman G; Firat D; Baltali E; Kansu E; Kars A; Ozisik Y; Ruacan S; Uzunalimoğlu B; Karaağaoğlu E
Jpn J Cancer Res; 1994 Dec; 85(12):1200-7. PubMed ID: 7531679
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and management of immunoproliferative small intestinal disease and primary small intestinal lymphoma in Pakistan.
Malik IA; Shamsi Z; Shafquat A; Aziz Z; Shaikh H; Jafri W; Khan MA; Khan AH
Med Pediatr Oncol; 1995 Nov; 25(5):400-6. PubMed ID: 7674998
[TBL] [Abstract][Full Text] [Related]
8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
[TBL] [Abstract][Full Text] [Related]
9. [Primary immunoproliferative small intestinal disease].
Nardulli Fernández G; Sukerman V; Marsicano L; Ramón Poleo JR; Hernández D; Almosny I; Olavarría R
G E N; 1995; 49(3):238-42. PubMed ID: 8598264
[TBL] [Abstract][Full Text] [Related]
10. [Intestinal non-Hodgkin lymphoma: "immunoproliferative small intestinal disease"].
Mrabti H; Raiss G; Raissouni S; Tazi el M; Inghaouen H; El Ghissassi I; Errihani H
Presse Med; 2011 Nov; 40(11):995-1000. PubMed ID: 21458210
[TBL] [Abstract][Full Text] [Related]
11. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V
J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577
[TBL] [Abstract][Full Text] [Related]
12. The cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine (COPBLAM-I) regimen for intermediate-grade non-Hodgkin's lymphoma. Long term follow-up in 51 patients.
Shpilberg O; Shiff J; Chetrit A; Ramot B; Ben-Bassat I
Cancer; 1994 Dec; 74(11):3029-33. PubMed ID: 7525042
[TBL] [Abstract][Full Text] [Related]
13. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
[TBL] [Abstract][Full Text] [Related]
14. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
15. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study.
Mauz-Körholz C; Hasenclever D; Dörffel W; Ruschke K; Pelz T; Voigt A; Stiefel M; Winkler M; Vilser C; Dieckmann K; Karlén J; Bergsträsser E; Fosså A; Mann G; Hummel M; Klapper W; Stein H; Vordermark D; Kluge R; Körholz D
J Clin Oncol; 2010 Aug; 28(23):3680-6. PubMed ID: 20625128
[TBL] [Abstract][Full Text] [Related]
16. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group.
Ben-Ayed F; Halphen M; Najjar T; Boussene H; Jaafoura H; Bouguerra A; Ben Salah N; Mourali N; Ayed K; Ben Khalifa H
Cancer; 1989 Apr; 63(7):1251-6. PubMed ID: 2920354
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of invasive thymoma. A retrospective study of 22 cases.
Göldel N; Böning L; Fredrik A; Hölzel D; Hartenstein R; Wilmanns W
Cancer; 1989 Apr; 63(8):1493-500. PubMed ID: 2466548
[TBL] [Abstract][Full Text] [Related]
18. Is immunoproliferative small intestinal disease uncommon in India?
Ghoshal UC; Chetri K; Banerjee PK; Choudhuri G; Pal BB; Dabadghao S; Dhar K; Naik S; Naik SR
Trop Gastroenterol; 2001; 22(1):14-7. PubMed ID: 11398237
[TBL] [Abstract][Full Text] [Related]
19. Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.
Eichenauer DA; Plütschow A; Kreissl S; Sökler M; Hellmuth JC; Meissner J; Mathas S; Topp MS; Behringer K; Klapper W; Kuhnert G; Dietlein M; Kobe C; Fuchs M; Diehl V; Engert A; Borchmann P
Lancet Oncol; 2017 Dec; 18(12):1680-1687. PubMed ID: 29133014
[TBL] [Abstract][Full Text] [Related]
20. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
